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Abstract 
Human cancer classification is currently based on the idea of cell of origin, light and electron 
microscopic attributes of the cancer. What is not yet integrated into cancer classification are 
the functional attributes of these cancer cells. Recent innovative techniques in biology have 
provided a wealth of information on the genomic, transcriptomic and proteomic changes in 
cancer cells. The emergence of the concept of cancer stem cells needs to be included in a 
classification model to capture the known attributes of cancer stem cells and their potential 
contribution to treatment response, and metastases. The integrated model of cancer classi-
fication presented here incorporates all morphology, cancer stem cell contributions, genetic, 
and functional attributes of cancer. Integrated cancer classification models could eliminate the 
unclassifiable cancers as used in current classifications. Future cancer treatment may be ad-
vanced by using an integrated model of cancer classification. 
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Introduction 
Human cancers occur worldwide. In 2008, 12.7 
million  new  cancers  and  7.6  million  cancers  were 
recorded; incidence and  mortality rates varied with 
regions and levels  of income around the  world (1). 
These  results  require  refocusing  on  all  attributes  of 
cancer. 
 Differentiating features of malignant and benign 
lesion  are  well  established;  these  include  rapid 
growth,  increased  cell  turn-over,  invasive  growth, 
metastases,  vascular  or  lymphatic  channel  invasion 
for malignant lesions. There are many exceptions to 
these attributes of cancer. There are overlaps between 
benign  and  malignant  lesions.  Benign 
(non-malignant) tumors do show chromosome aber-
rations; uveal melanomas and blue nevi share muta-
tions in G protein (2). A good example is the recent 
attempt  among  dermatopathologists  to  segregate 
some  melanocytic  lesions  as  atypical  melanocytic 
proliferations  with  low  malignant  potential 
(MELTUMP)  (3).  Sometimes  a  cancer  at  given 
site/organ is classified as containing two cell types; 
for example, pancreatic cancer with neuroendocrine 
and acinar/ductal components (4). What model can 
accommodate unclassifiable cancers in a specific loca-
tion? Cancer classification schemes always reserve a 
group as unclassifiable. How can this group be elim-
inated? 
The last two decades have witnessed the surge in 
molecular profiling (5, 6) and has already expanded 
into predictive and diagnostic molecular classification 
of cancers (7, 8). As in the diagnosis of cancers, current 
molecular  classification  schemes  are  still  dependent 
on  morphologic  variables.  These  classifications 
schemes use cell of origin as seen by light and electron 
microscopy. Inherently, all organs can generate mul-
tiple cancer types as multiple cell types exist in these 
organs-  “the  holy-grail  of  all  subspecialties”.  Fur-
thermore,  cancer  subtypes  are  generated  under  the Journal of Cancer 2011, 2 
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banner of a single, specific cell type of origin concept. 
Take the example of the common Basal cell carcino-
ma-  it  has  variants  and  subtypes  such  as  nodular, 
superficial, adenoid, morpheaform, infiltrative, kera-
totic, pigmented, basosquamous, clear cell, granular, 
eccrine, apocrine, fibroepitheliomatous, adamantoid, 
and basosebaceous (9). Do these entities have unique 
biological features or simply morphological variants 
of interest only to the diagnostic pathologists? Will the 
“cancer stem cell origin concept” cure this malady? 
The current move to genomics {(gene and tran-
scripts, kinomes, microRNAs, single nucleotide pol-
ymorphisms  (SNPs),  gene  copy  number  variation 
(CNVs)  and  proteomics  (antibody  microarray  and 
mass spectrometry)} brings change to the diagnostic 
information  needed  for  treatment.  Along  with  the 
genomic  profiling,  are  efforts  at  targeted  and  gene 
therapy.  Because  of  accumulated  experience,  in  di-
agnosis,  classifications  and  treatment  of  cancer  that 
depends on morphology, the shift to genomic meth-
ods  should  be  comprehensive  and  adequate  for 
day-to-day clinical use. While future cancer classifica-
tion schemes or models may not require morpholog-
ical attributes, current dependencies on morphologi-
cal phenotype requires its inclusion (10-12). Morpho-
logic cancer phenotyping does not need to hide the 
compendium of genetic alterations, interactions with 
environment  and  alterations  in  transcriptional  and 
protein  interaction  networks  that  are  present  in  all 
cancers (11, 13). 
Hallmarks of Cancer Cell  
Hanahan and Weinberg (2000) (14, 15) listed the 
seven attributes of cancer; 1) Self sufficiency in growth 
signals,  2)  Insensitivity  to  anti-growth  signals,  3) 
Evading apoptosis, 4) Limitless replicative potential, 
telomerase and telomeres 5) Sustained angiogenesis, 
6)  Tissue  invasion  and  metastasis,  and  7)  Genome 
instability.  All  seven  attributes  have  received  great 
attention in the past decade. Growth and anti-growth 
signaling are really complex (13). Protein-protein in-
teraction  and  signaling  networks,  growth  signaling 
pathways,  the  role  of  ubiquitination  and  protein 
degradation,  and  dysfunctional  protein  networks 
(16-18)  and  interactions  are  complex,  described  as 
hubs, modules and motifs (13). Information on cancer 
cell death and provocation by drugs and irradiation 
now  requires  all  cell  death  types  to  be  considered- 
apoptosis, necrosis, autophagy (19, 20). We now must 
include the pivotal role of microRNAs (21, 22), and 
methylation  patterns  (23).  For  example,  mi-
croRNA-185  suppress  cancer  growth  by  interfering 
with Six1; when absent in cancers leads to increase 
growth and progression (24). Recent efforts have un-
covered  the  role  of  transposons  in  the  induction  of 
cancer in mouse models; the studies are generating 
previously unknown cancer related genes (25). Class 
II  (DNA  transposons)  and  class  I  retrotransposons 
contribute  to  DNA  instability  (26).  Cancer  cells  use 
aerobic  glycolysis  to  meet  energy  needs  (Warburg 
effect) and presumed to be a response to hypoxia and 
tumor  micro-environment;  changes  in  metabolic 
needs of cancer cells such as need for glutamine and 
activation  of  hypoxia-inducible-factor  (HIF)  are  in-
terconnected  to  oncogene  activation  (27-29).  These 
interacting  functionalities  of  cancer  cells  impact 
prognostic and predictive models based on one or two 
functional attributes of cancer (30). 
Origin of Cancer Cells –The Cancer Stem 
Cell Model 
The  traditional  model  of  cancers  envisaged  a 
“normal cell” transformed to “atypical or dysplastic“ 
cell with progression into invasive of malignant cell. 
This is the model that only assumes stochastic gener-
ation of cells capable of the behavior of metastasis and 
progression and cellular heterogeneity of cancers. The 
stochastic model is used to explain heterogeneity in 
cancers  such  as  in  prostate  cancer  (Fig  1).  The  sto-
chastic model will have to assume that all genetic ab-
errations  conferring  advantages  to  the  cancer  cells 
“must be maintained in all subsequent cells as growth 
and proliferation continues and some maturation oc-
curs”.  As  cancers  can  also  undergo  senescence, 
apoptosis,  autophagy  and  necrosis,  the  stochastic 
model must account for these changes (31, 32). Cancer 
senescence occurs via telomere shortening, oxidative 
stress, and oncogene activation, that can impair cancer 
progression  (33-35).The  stochastic  model  has  to  ac-
count for local recurrence and metastasis after long 
post-treatment intervals. Cell of origin models cannot 
exclude all interactions between cancer cells and any 
influence from the stroma (36, 37). Recent computa-
tional  stochastic  models,  in  part  based  on  the  hall-
marks of cancer, suggest that onset of cancers depend 
on  the  first  two  (2)  mutations  and  early-onset  and 
late-onset cancer initiate these mutations at different 
times  (38).  Cancer  initiation  via  DNA  damage  re-
sponse and repair, induction of senescence and p53 
mutation (39), the generation of driver mutations can 
be accommodated in stochastic and cancer stem cell 
models.  Driver  mutations  in  cancer  initiation  are 
suggested  to  accumulate  over  time.  Recent  detailed 
studies of human cancers and cancer cell lines show 
extensive  and  highly  localized  mutations  following 
DNA damage and repair response; 2-3 % of human 
cancers develop these single chromosome mutations 
labeled as chrothripsis and are suggested as the gene-Journal of Cancer 2011, 2 
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sis of driver mutations generated (40). There are no 
unique driver mutations for the stochastic model. 
 
 
 
 
Figure 1. Patterns and heterogeneity in Cancerous Pros-
tate  Tissue  (Hematoxylin  and  eosin  stain).  A.  Normal 
prostate showing luminal and basal cells. B. Prostate cancer 
with definable glandular pattern, usually part of Gleason 
pattern 3. C. Prostate cancer with aggregation, clustering or 
individual infiltrating cells as described for Gleason 4. 
 
Cancers of certain presumed cell types, synovial 
cells, occur in locations without defined synovium or 
other related cell type. Clear cell sarcoma is seen in 
deep soft tissues and is a copy of all features of mel-
anoma  except  for  genetic  aberrations.  How  do  we 
explain  these  cancers  on  the  cell  of  origin  concept? 
Prostate cancer cell of origin thought to be luminal 
cells, are now shown to be derived from basal cells 
with the attributes of androgen-independence (41). 
The cancer stem cell model has been used to ex-
plain  cancer  cell  origin,  initiation,  progression  and 
metastasis (42-44) (Fig 2). Cancer stem cells as origin 
of cancers has attributes of hierarchical organization, 
may be under-estimated and assumed to be a minor 
population (45, 46). As in their resident or embryonic 
stem  cell  counterparts,  there  are  known  regulators, 
such  as  p53  and  WNT  signaling  pathways.  Cancer 
stem cells show c-Myc transcription profile, similar to 
embryonic  stem  cells  (47).  These  cancer  stem  cells, 
initially described in breast cancers (48), are now de-
scribed in liver, ovarian, prostate, head and neck, co-
lon and brain cancers, melanomas (49-54). The cancer 
stem  cells  have  their  specific  microenvironments  to 
allow for their specific functions; epigenetic modifica-
tions may  make cancer stem cells  not reliant on its 
specific niche (42). Cancer stem cells are usually pro-
jected as a minor population of all cancer cells (46, 55). 
The number of identified cancer initiating stem cells 
may be affected by the background of animals used in 
xenotranspnatation;  in  a  mouse  xenograft  model  of 
melanoma,  25%  of  cancer  initiating  cells  could  be 
found (50). 
The  functional  attributes  of  cancer  stem  cells 
such as (i) evasion of cell death, i.e apoptosis, (ii) te-
lomere activation, (iii) colony formation, tumor initia-
tion and differentiation are suited to their role in hu-
man cancer (45). The contribution to recurrence, me-
tastasis  and  treatment,  especially  radiothera-
py-resistance,  is  now  better  appreciated  (56,  57). 
Cancer stem cell markers for several human cancers 
are listed in Table 1. Cancer stem cells markers have 
functional attributes such  as adhesion, cell invasion 
(CD44) and interactions with GLI1 and focal adhesion 
kinase (FAK) (CD24) (58). 
Table 1. Biomarkers for Human Cancer Stem Cells 
Cancer Type  Markers 
Breast  CD44+CD24_/low 
Ovary 
 
CD133+/CD44+, CD117, 
Oct4, STELLAR, Nanog and 
ABCG2/BCRP1   
Lung  Cd133+(ABCG2, Oct4, ESA) 
Brain  CD133+ 
Colon 
 
CD133+ CD44+ EpCam+, CD166+ 
(CD29+, CD24+) 
Pancreas  CD44+EpCam+ CD24+ Journal of Cancer 2011, 2 
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Figure 2 Comparison of Stem Cell and Lineage/Clonal Evolution Models of Cancer Cell Origin. (a)The lineage/clonal 
evolution model is used in morphological classification of cancer. One cell type gives rise to one cancer type. Squamous 
epithelium gives rise to squamous cell carcinoma. Pathologists do encounter squamous cell carcinoma in the urothelium of 
the urinary bladder. How we explain this is by “metaplasia of urothelium to squamous epithelium” and perhaps then to 
squamous cell carcinoma. An easier explanation will be cancer stem cell model as these have the capacity to become any cell 
type. (b) Cancer stem cells, with their inherent functional capacities including reduced cell death, are of interest when 
cancers are treated by irradiation or chemotherapy. Human cancers, examined in detail and extensively, do contain het-
erogeneous cell types; lung cancers are a good example. This leads to difficulties in some classification schemes depending on 
lineage. Journal of Cancer 2011, 2 
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Cancer Metastases and Cancer Stem Cell 
Model 
Cancer  metastasis  occurs  either  through  pro-
gressive  acquisition  of  metastatic  potential  or  the 
traits are acquired early during cancer initiation; this 
implies that metastases occurs early or late in cancer 
(59-61). The acquired traits include survival and eva-
sion of cell death, dormancy, migration, immune es-
cape, and ability to seed, home on targets (62). Sup-
port for late evolution of metastasis was described in 
pancreatic  cancer  using  genome  sequencing  ;  this 
study indicated clones with metastatic capacity evolve 
late ( 5years), and are present in the primary tumor 
(63, 64). Breast cancer cells reaching the bone marrow 
share stem cell features and markers CD24 and CD44 
as  determined  by  double  immunohistochemistry  in 
bone  marrow;  these  stem-like  cells  ranged  from 
33-100%  in  metastases  (65).  CD26+CD24+  positive 
cancer  cells  found  in  colon  cancers,  not  initiating 
CD133+CD26+CD44 positive cells, define occurrence 
of metastases (66). Some have separated cancer stem 
cells  from  pancreatic  cancers  capable  of  initiating 
metastases (67). 
Personalized Genomic Medicine and Cancer 
Classification 
How  will  the  push  for  personalized  medicine 
affect the present morphology based and the future 
trend of molecular cancer classification? Personalized 
medicine, as envisioned will require individual cancer 
genomics  and  proteomics  for  maximum  benefit  of 
targeted treatment for the individual; the implications 
of genomic cancer medicine should encourage use of 
integrated cancer classification models (68-73).  
Integrated Model of Cancer Classification 
The model envisaged (Fig 3) takes into account 
all elements of a cancer. We now can provide mor-
phologic classes and subtypes, extract proteomic and 
gene  profiles  and  gene  copy  number  variations  in-
cluding cytogenetic and array comparative genomics. 
An added feature is that the functions of proteins and 
signaling pathways can be derived from gene expres-
sion and proteomics. This means that altered or dys-
functional pathways can be supported by adding cy-
togenetic or CNV data. There are emerging integrated 
models  that  use  both  genomics,  exon  resequencing, 
and  proteomics  in  cancer  analysis  (74-76).  Recent 
prostate cancer survival and post-surgical recurrence 
used  modeling  based  on  some  aspects  of  the  inte-
grated  classification  model  including  mutation  pat-
terns,  CNVs,  targeted  signaling  pathway  deregula-
tion,  miRNA  and  cDNA  profiling;  new  oncogenes, 
and  CNV-based  disease  risk  profiles  over  above 
morphology grades were found (77). 
 
 
Figure  3 Figure  Model of  Cancer Classification. In this 
model,  the  Phenotype  is  represented  by  Morphological 
Characteristics/and  subtypes;  Proteomic  profile  can  be 
derived from high-throughput tissue microarrays and im-
munohistochemistry  plus  automated  computer-assisted 
quantitation with normalized intensities, protein microar-
rays and mass spectrometry; array comparative genomics 
for Copy Number Variation(CNV) and chromosomal ab-
errations, Genomic profiling using cDNA microarrays, and 
finally microRNA profiling. This provides protein profile and 
cDNA profiles for Gene Ontology and functional annota-
tion. Signally pathways active or repressed can be derived. 
The  CNV  and  microRNA  data  provide  information  to 
explain  active  oncogene  induced  pathways  and  miRNA 
targeted pathways that impact proliferation, cell survival, 
metastasis etc.  
 
1) Proteomics: Normal and cancer tissues can be 
used  for  comparative  proteomics.  The  methods 
available  are  mass  spectrometry,  protein  and  anti-
body  microarray  and  tissue  microarray.  In  mass 
spectrometry, tissue and cell protein content is quan-
titatively  determined  by  analyzing  peptide  content 
and  via  bioinformatics  the  protein  content,  protein 
types  and  classes,  protein  interaction  networks  and 
via gene ontology functional protein mapping (78-80). 
Tissue  microarray  uses  tissue  cores  for  immuno-
histochemistry and indirect analysis of protein levels 
(81-83). In antibody and protein-antigen arrays, pro-
tein or antibody spotted on an array is probed with 
fluorophore-labelled  protein  or  antibody  and  ana-
lyzed like cDNA microarrays (84-87). Flow cytometry 
can be used to catalogue both surface membrane, cy-
toplasmic  and  nuclear  proteins  in  cells.  Mass  spec-
trometry,  tissue  microarray  can  be  used  to  validate 
other profiling methods. Mass spectrometry is quan-
titative and can estimate both modified and unmodi-Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
112 
fied  proteins;  2-dimensional  gel  electrophoresis  and 
protein isolation can be followed by mass spectrome-
try (78, 80, 88, 89). Glycomics and glycan profiling can 
add to the protein profile using both mass spectrom-
etry and lectin microarrays to generate aberrant cell 
migration (90, 91). 
2) cDNA Profiling and Transcriptomics; cDNA 
microarray  profiling  is  the  most  common 
highthroughput  method  for  determining  expression 
levels  of  mRNA  in  cells  and  tissues  (5).  Isolated 
mRNA  is  transformed  to  cDNA,  which  is  used  to 
probe optimally designed oligonucleotide array that 
helped to generate new classes of breast cancer, leu-
kemias  and  lymphomas.  Using  transcriptomics  for 
clinical cancer treatment is an area of intense research 
( translational research) ( 12, 68, 72). Direct RNA se-
quencing  overcomes  drawbacks  of  cDNA  based 
methods, detect low quantities of mRNA, detect chi-
meric transcripts, can use RNA from fixed tissues, and 
uses sequencing-by-synthesis (92). 
3). Copy Number variatiopn (CNV): Normal and 
cancer  cells  show  variations  in  genes.  The  most 
common  variation  is  single  nucleotide  polymor-
phisms (SNPs). Variations greater than 1kilobase of 
DNA  is  called  CNV.  Other  variations  include  mi-
crosattelite  instability  (MSH),  variable  tandem  re-
peats,  transposable  elements,  deletions,  inversions, 
and  duplications.  Furthermore,  transcripts  of  gene 
fusions provide a wealth of information on the func-
tional input of fused genes(64, 93-97) 
4). Methylation status: Gene promoter methyla-
tion at the cytosine-guanine sites (CpG islands) leads 
to  gene  transcription  suppression.  Demethylation 
leads  to  transcript  activation.  Methylation  status  of 
cancer  genes  adds  complexity  to  interpretation  of 
gene  profiling.  Finding  methylation  status  involves 
use of(i) methylation-sensitive or methylation-specific 
endonucleases, (ii) Sodium bisulphate treatment and 
DNA sequencing (iii) target amplification by capture 
and ligation (23, 98, 99). 
5). miRNA Profiling: microRNAs (18-24 nucleo-
tides) are present in plants and animals. miRNAs play 
significant roles in normal development, cellular re-
sponses  and  in  human  cancer.  miRNAs  represses 
mRNA trascription via partial complimentary align-
ment with targer mRNAs. miRNA profiling adds to 
complexity of cancer cell and tissue profiling. Align-
ment with their targets tells us why certain transcripts 
may be down-regulated (22, 100-105). 
 6). Gene Sequencing: Human genome sequenc-
ing ushered in the grand promise of genomics medi-
cine  in  2000.  Now  individual  genes  and  chromo-
somes, and gene fusions are sequenced; these efforts 
will have impact on the information sets necessary for 
diagnosis, treatment and predicting outcome in can-
cer  (38).  This  enables  direct  analysis  of  mutations 
within the gene components of interest. Gene annota-
tion enables linking of sequences to active transcripts 
(96). Next generation sequencing can overcome some 
drawbacks of qPCR and cDNA microarray and can 
enable  assessment  of  cancer  gene  mutations,  copy 
number  variations  (CNV),  SNPs,  miRNA  and  tran-
scription  profiling  (106).  Emerging  sequencing 
methods,  labeled  third  generation  sequencing,  in-
clude  single-molecule-real-time  sequencing  (SMRT), 
direct sequencing using direct imaging and sequenc-
ing using nanopores (107). 
 7). Cancer Grading: Cancer grading to reflect the 
extent  of  differentiation  is  done  for  many  cancers. 
Grading  systems  vary  and  depend  on  cancer  type. 
Morphologic  attributes  are  used  to  grade  (score) 
prostate cancer (108, 109). Cancer grades will form an 
integral  part  of  the  model.  Cancer  stem  cell  com-
partment within the tumor can be estimated by pro-
teomics-  immunohistochemical  methods  using  anti-
bodies to CD24, CD44, CD133 and CD26.  
The  integrated  model  can  be  generated  using 
comprehensive bioinformatics and data mining tools. 
OmicsAnalyzer is one such tool, which is a plug-in for 
Cytoscape (cytoscape.org), a web based platform for 
protein/gene  network  modeling,  functional  annota-
tion and analysis. (110). Bioinformatics tools for clas-
sification, data mining and modeling are available ( 
R-project.org). The integrated model of cancer classi-
fication can help stratify individuals for target treat-
ment  and  disease  outcome  based  on  the  treatment 
(Table 2).  
Table 2. Anticipated data sets from a biopsy for decision 
making in targeted cancer treatment. Gene profiling sig-
natures (growth, oncogene and stemness), and proteomics 
can be correlated with CNVs, mutations and gene fusions. 
Protein interaction maps can suggest treatment targets, 
possible pathways of resistance. 
Cancer morphology 
 
 
Adenocarcinoma, Grade 2 
10% Mucinous component 
10% Cancer stem cells 
Proteom-
om-
ics/Transcriptome/
Methylome 
 
 
Up-regulated cell death pathway 
Up-regulated growth factor signaling  
Hyper-methylation of kinases 
Decreased expression of autophagy pathway 
miRNA clusters in some autophagy genes 
De-regulated metabolic genes  
Mutations (Sequenc-
ing/CNV) 
 
 
 
 
 
Mutations in 24 genes 
Gene fusions 
Copy number changes in 10 genes 
Clustered mutations in 8 genes 
BRAF, KRAS, EGFR, and p53 mutations  
 Journal of Cancer 2011, 2 
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Conclusion 
Cancer  cells  are  endowed  with  capacities  for 
uninhibited  proliferation,  invasion  and  metastasis. 
Cancer initiation, driver mutations, progression and 
metastases are common attributes for both stochastic 
and cancer stem cell models; cancer stem cells possess 
attributes that enhance survival in all environments 
hence  more  suitable  as  model  of  cancer.  Integrated 
models that capture every essence of a cancer could 
enhance the ability to target different components of 
cancer for maximum therapeutic effect. 
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